Mercyhealth is seeking healthy volunteers to provide six vials of blood and some health information such as name, date of birth, and family medical background. Blood samples from healthy volunteers will be compared to cancer patient volunteers in order to develop a blood test designed to detect multiple types of cancer at the earliest stage possible. After completion of the study you will be compensated for your participation.
If interested, please email firstname.lastname@example.org or call the Mercyhealth Cancer Center—Janesville Research Office at (608) 756-6695 or Mercyhealth Cancer Center—Rockford Research Office at
A011801 – The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
NRG BR004 – NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
NRG BR003– A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node Negative Triple-Negative Invasive Breast Cancer
SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Rumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Alliance A021703: Randomized Double-Blinded Phase III Trial of Vitamin D Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer.
S1613– A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non?Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature?driven Analysis
LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
EA2185 – Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Multiple Cancer Sites
EAY131 – Molecular Analysis for Therapy Choice (MATCH)
THR-CS-001– Detecting cancers Earlier Through Elective plasma-based CancerSEEK testing-Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND2)